Track Lyka Labs Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: 6.05 %
Low
70.5
High
76.6
1 Month returns: 13.99 %
Low
58.0
High
76.6
1 Year returns: -26.85 %
Low
44.1
High
104.8
3 Year CAGR: -15.73 %
Low
44.1
High
176.6
5 Year CAGR: -1.40 %
Low
44.1
High
267.0
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Lyka Labs Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Lyka Labs Ltd. Shareholding Pattern
Quarterly breakdown of Lyka Labs Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Lyka Labs Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Lyka Labs Ltd.?
The current share price of Lyka Labs Ltd. is ₹ 73.59 as of 25 Aug 2026.
What is the market capitalisation of Lyka Labs Ltd.?
The market capitalisation of Lyka Labs Ltd. stands at ₹ 271.47 Cr.
What is the PE ratio of Lyka Labs Ltd.?
The Price-to-Earnings (PE) ratio of Lyka Labs Ltd. is - as of the latest trailing twelve months data.
What is the ROE and ROCE of Lyka Labs Ltd.?
Lyka Labs Ltd. has a Return on Equity (ROE) of -10.24% and a Return on Capital Employed (ROCE) of -8.44% as per the latest financial reports.
What is the 52-week high and low of Lyka Labs Ltd.?
The 52-week high of Lyka Labs Ltd. is - and the 52-week low is -.
What is the dividend yield of Lyka Labs Ltd.?
The dividend yield of Lyka Labs Ltd. is 0.00% based on the current market price.
What is the FII and DII holding in Lyka Labs Ltd.?
Foreign Institutional Investors (FII) hold 0.17%, Domestic Institutional Investors (DII) hold 0.29% and retail/public investors hold 36.33% of Lyka Labs Ltd. shares.
What sector does Lyka Labs Ltd. belong to?
Lyka Labs Ltd. operates in the Healthcare sector.
What is the beta of Lyka Labs Ltd.?
The beta of Lyka Labs Ltd. is 1.09, indicating its price volatility relative to the broader market. Over the past 1 year, Lyka Labs Ltd. has delivered an absolute return of -24.54%.
What is the RSI of Lyka Labs Ltd.?
The 14-day Relative Strength Index (RSI) of Lyka Labs Ltd. is 67.41, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.
Stock Analysis
Fundamental analysis overview of Lyka Labs Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.53 as on 30 Jun 2026 and Debt to Equity increased marginally by 0.15 in the last 1 year
What is Debt to Equity?
Negative
Stock is fairly expensive with negative EPS on a trailing 12-month basis
Earnings yield of -3.28% indicates that the stock is very expensive and has a negative EPS on a trailing 12-month basis
What is Earnings yield (E/P)?
Low and declining ROE
The company reported low ROE of -10.24% for 12-month ended 30 Jun 2026 and ROE declined by -1956 bps from 1 year ago
What is ROE (FY)?
Low and declining operating margin
The company reported low operating margin of -7.97% for 12-month ended 30 Jun 2026 and operating margin declined by -1560 bps from 1 year ago
What is Operating profit margin?
Low revenue growth and lower than median growth of industry
The company delivered moderate revenue growth of -2.6% for 12-month ended 30 Jun 2026 and the growth was 13.19 percentage points lower than median growth of industry
What is Sales growth (1Y)?
Median: 10.59
Value -2.6
-99.6111701.8
Low EPS growth and lower than median growth of industry
The company delivered moderate EPS growth of -219.68% for 12-month ended 30 Jun 2026 and the growth was 226.88 percentage points lower than median growth of industry
What is EPS growth (1Y)?
Low dividend yield
The company has a low dividend yield of 0.0%
What is Dividend yield?
Neutral
Company's earnings are of moderate quality
Earnings quality score of 53.9 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
53.9 / 100
Stock in ESM list
The stock has been places in Enhanced Surveillance Measure (ESM) list (ESM - II (35)).
Thinly traded (low daily turnover)
The stock is thinly traded with combined (NSE & BSE) daily turnover (21-day average) of 0.130645.
Mar 2020
Jun 2020
Sep 2020
Dec 2020
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Promoter
19.88
19.88
19.88
19.88
19.88
19.88
20.00
20.04
47.79
47.80
47.59
47.59
51.00
54.58
54.81
54.81
54.81
58.10
58.10
58.10
58.16
58.16
58.16
58.16
58.16
58.45
Indian Promoter
19.88
19.88
19.88
19.88
19.88
19.88
20.00
20.04
47.79
47.80
47.59
47.59
51.00
54.58
54.81
54.81
54.81
58.10
58.10
58.10
58.16
58.16
58.16
58.16
58.16
58.45
Foreign Promoter
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Institutions
4.16
4.15
3.97
3.97
3.97
3.97
3.92
1.60
2.31
4.75
4.57
4.37
3.92
0.58
0.59
0.79
0.98
0.90
0.82
0.82
0.90
0.83
0.84
0.84
0.96
0.83
Mutual Funds / UTI
0.01
0.01
-
0.01
0.01
0.01
1.39
0.01
0.73
3.54
3.54
3.54
3.31
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
FI/Bank/Insurance
0.47
0.46
0.47
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.43
0.40
0.40
0.40
0.40
0.37
0.28
0.28
0.28
0.28
0.28
0.28
0.28
0.28
Govt
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
FII
3.50
3.50
3.50
3.50
3.50
3.50
2.07
1.13
1.12
0.76
0.57
0.37
0.18
0.17
0.18
0.17
0.17
0.15
0.15
0.15
0.24
0.16
0.17
0.17
0.29
0.17
Other Institutions
0.18
0.18
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.21
0.40
0.37
0.37
0.37
0.37
0.37
0.37
0.37
0.37
0.37
Non-Institution
75.96
75.97
76.15
76.15
76.15
76.15
76.08
78.36
49.89
47.45
47.84
48.05
45.08
44.85
44.60
44.40
44.21
40.99
41.08
41.07
40.94
41.01
41.00
41.00
40.88
40.72
Bodies Corporate
4.94
4.85
1.97
5.06
4.95
1.63
6.47
34.91
7.33
4.68
3.87
3.77
4.63
5.40
5.49
5.95
5.78
5.48
5.08
4.90
5.44
5.25
4.17
4.35
4.47
4.39
Others (incl. Retail)
No. of shareholders
71.02
19,454
71.12
19,848
74.18
19,666
71.09
19,515
71.20
19,204
74.52
21,975
69.61
20,508
43.45
27,537
42.56
26,006
42.77
26,751
43.97
28,208
44.28
28,301
40.45
26,607
39.45
26,977
39.11
26,441
38.45
26,214
38.43
25,522
35.51
25,529
36.00
28,735
36.17
28,898
35.50
28,271
35.76
27,988
36.83
27,564
36.65
26,981
36.41
26,559
36.33
29,172
Company Profile
Overview of Lyka Labs Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Lyka Labs Limited is an India-based pharmaceutical company engaged in the development, manufacture and marketing of quality finished dosages. The Company manufactures pharmaceutical products such as Dry Powder, Liquid, Lyophilized Injections and External Preparations for several International Markets and the Domestic Market. The Company’s R&D is engaged in the development of new formulations and has developed several products in the categories, such as Injectables: Lyophilized Injection, Liquid Injections & Dry Powder Injections, and Topical Preparation: Ointment /Creams and Lotions. It offers formulations, such as emollient, anti-aging, cleansing lotion, hair care products, anti-dandruff shampoo, sunscreen, anti-acne, antioxidant tablets, antioxidants combination, proton pump inhibitor, antifungal, anti-malarial, antibacterial, corticosteroid hormones and cephalosporins. The Companys subsidiaries include Lyka BDR International Limited and Lyka Exports Limited.
Lyka Labs Limited is an India-based pharmaceutical company engaged in the development, manufacture and marketing of quality finished dosages. The Company manufactures pharmaceutical products such as Dry Powder, Liquid, Lyophilized Injections and External Preparations for several International Market...
Key personnel
Mr. Babulal JainD
Independent Chairman of the Board
Mr. Kunal Narendra GandhiD
Chief Executive Officer, Managing Director, Executive Director
Mr. Yogesh B. ShahD
Chief Financial Officer, Whole-Time Director
Mr. Prashant GodhaD
Additional Director
Mr. Shashil MendonsaD
Additional Director
Shri. Vinod S. ShanbhagD
Additional Independent Director
Mr. Neeraj GolasD
Additional Non-Executive Independent Director
Ms. Archana YadavD
Additional Non-Executive Independent Women Director